Skip to main content

QNTM · Quantum Biopharma Ltd.

Track QNTM — free
$1.42 -0.10 (-6.58%) At close · Nov 19
Market Cap
$9.13M
Shares
6.43M
Volume · Nov 19 78.98K Avg daily vol (3M) 149.43K

Price & Indicators

 

Key stats

Close
$1.42
Open
$1.55
Day range
$1.38–1.64
52-week closing range
$1.42–11.41
Average volume, 30 days
109K
Short interest
440K · 6.8% of shares · 4.5 days
Short volume, last session
47%
Price history
Jan 2020 to Nov 2026

Latest documents

2026
Nov 13
Current report 6-K
Shareholder equity rises 91% as Lucid-MS trial advances

Quantum BioPharma Ltd. reported 91% shareholder equity growth to US$9.77 million and US$12.22 million in combined cash and digital assets as of September 30, 2026. It also signed a study start-up agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial.

2 source passages
As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (excluding US$1.60 million of digital assets that were restricted at that date). Total shareholders’ equity increased approximately 91% to US$9.77 million, from US$5.10 million at December 31, 2025. Subsequent to quarter-end, the Company entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS in progressive multiple sclerosis, following the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA) in August 2026. Open the document at this passage
Nov 12
Current report 6-K
Nine-month net loss narrows to 17,320,779

Quantum Biopharma Ltd. reported a nine-month net loss of 17,320,779, down from 23,253,808, while period-end cash reached 3,556,345 and digital assets totaled 8,658,775.

Read from the first part of this long document
5 source passages
Quantum Biopharma Ltd. Nine months ended September 30, | | 2026 | 2025 Net loss | | (17,320,779) | (23,253,808) Cash and cash equivalents, end of the period | | 3,556,345 | 445,944 Digital assets | 6,10 | 8,658,775 | 2,213,575 Open the document at this passage
Nov 12
Current report 6-K
Closing raises C$80.86, voting power reaches approximately 68.22%

Quantum BioPharma raised C$80.86 by privately placing 26 Class A Multiple Voting Shares on November 9, 2026, lifting voting power to approximately 68.22%. Shareholders authorized consolidation of up to ten (10) pre-consolidation shares for one (1) post-consolidation share.

3 source passages
On November 9, 2026, the Company closed the Offering, issuing 26 Class A Multiple Voting Shares at a price of C$3.11 per Class A Multiple Voting Share for aggregate gross proceeds of C$80.86. Following the Offering, the 68 outstanding Class A Multiple Voting Shares represent approximately 68.22% of those votes. approved a special resolution authorizing the Board, in its sole discretion, to consolidate the Company’s issued and outstanding Class A Multiple Voting Shares and Class B Subordinate Voting Shares at a ratio of up to ten (10) pre-consolidation shares for one (1) post-consolidation share, as determined by the Board Open the document at this passage
Nov 5
Current report 6-K
70% MVS voting cap applies if cancellations exceed threshold

Quantum BioPharma Ltd. corrected fractional-share rounding for its proposed consolidation and clarified that the 70% cap on MVS holders’ voting power applies only if Class B Subordinate Voting Share cancellations would raise their aggregate voting power above 70%.

3 source passages
Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that it has filed a supplement (the “Supplement”) to its management information circular dated September 28, 2026 (the “Circular”) in connection with the annual general and special meeting of shareholders of the Company scheduled for November 10, 2026 at 1:00 p.m. (Eastern time) (the “Meeting”). The correction clarifies the treatment of fractional shares resulting from the consolidation. The Company also wishes to clarify that, in the event any Class B Subordinate Voting Shares are purchased for cancellation or otherwise cancelled such that the holders of MVS would thereby hold more than 70% of the aggregate voting power of the Company, the Company will implement a measure to ensure that, notwithstanding such holders’ aggregate voting power exceeds 70%, their voting power will be capped at 70%. Open the document at this passage
Oct 8
Current report 6-K
Current report

Quantum BioPharma Ltd. announced that the United States District Court for the Southern District of New York consolidated its direct action and an investor-led class action alleging market manipulation, appointing Grant & Eisenhofer P.A. as lead counsel.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-99.2%
Year over year · fewer shares
Price change (1Y)
-77.5%
Trailing year
Short interest
6.8%
Latest settlement · 4.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −61%
below
Price vs 50-day avg −48%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −37%
trailing
6-month return −73%
trailing
YTD return −81%
this year
Relative strength −67%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.84% of shares out · ▼ -15.4% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
28 holders — near 3-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 142%
annualized · 1-yr
Max drawdown −88%
past year
ATR 14.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−61% Bearish
Price vs 50-day avg
−48% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+8% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
6.84% of shares out · ▼ -15.4% MoM · 4.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
28 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $11
vs 200-day avg -61% vs 50-day avg -48%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QNTM
Quantum Biopharma Ltd.
this stock
$9.13M -80.5% — — 6.8%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
28
% held
8.5%
Net QoQ
+133.5K sh
Top holder
AdvisorShares Investments…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
440.0K
Days to cover
4.5d
Change
-80.0K sh
View
Short Volume
Short vol %
47%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
9.2K
Value
$22.5K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
52.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 13, 2026
This year
31

Quantum BioPharma Ltd. reported 91% shareholder equity growth to US$9.77 million and US$12.22 million in combined cash and digital assets as of September 30, 2026. It also signed a study start-up agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial.

View
Earnings & Events
Webcasts
Last webcast
May 21, 2025
View

Performance

5D 20D 120D MTD YTD
QNTM -20.2% -37.4% -73.0% -40.3% -80.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -14.8% -31.2% -67.3% -35.1% -85.5%
Key facts CIK 1771885 CUSIP 74764Y205 13F (30d) 28 filings 26 filers Visit website Investor relations